{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:33:22Z","timestamp":1785429202574,"version":"3.56.0"},"reference-count":66,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy of Craiova"},{"id":[{"id":"https:\/\/ror.org\/031d5vw30","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Background: Hyperuricemia is a prevalent comorbidity in psoriatic arthritis (PsA), yet its influence on the IL-1\u03b1\/IL-17 cytokine balance remains unexplored. We aimed to characterize serum IL-1\u03b1 and IL-17 profiles in PsA stratified by hyperuricemia status and to compare these with patients with hyperuricemia without psoriatic disease (HU). Methods: This cross-sectional study included 34 consecutively recruited PsA patients (19 hyperuricemic, 15 normouricemic) and 30 HU controls. Serum IL-1\u03b1 and IL-17 were measured by ELISA. The PsA cohort was stratified by hyperuricemia status, cutaneous psoriasis, disease pattern, obesity grade, hypertension, sex, and enthesitis. Between-group comparisons used Mann\u2013Whitney U and Kruskal\u2013Wallis tests with Bonferroni-corrected post hoc analyses. Bivariate associations were assessed using Spearman\u2019s rank correlation. Results: Within the PsA cohort, hyperuricemic patients had significantly lower IL-17 than normouricemic patients (31.1 \u00b1 15.7 vs. 49.5 \u00b1 25.3 pg\/mL; p = 0.01), while IL-1\u03b1 did not differ significantly (37.3 \u00b1 11.7 vs. 34.0 \u00b1 8.19 pg\/mL; p = 0.24). No correlation was observed between IL-1\u03b1 and IL-17 (\u03c1 = \u22120.05), indicating independent immunological axes. In the three-group comparison, IL-17 differed significantly across PsA-normouricemic, HU, and PsA-hyperuricemic subgroups (p = 0.022), whereas IL-1\u03b1 was comparable across all three groups (p = 0.584). None of the traditional clinical classifications\u2014disease pattern, cutaneous psoriasis, or sex\u2014were significantly associated with either cytokine. Conclusions: Hyperuricemia was associated with significantly lower circulating IL-17 in PsA without a corresponding change in IL-1\u03b1 levels, and this association appeared more pronounced within the inflammatory context of psoriatic disease than in hyperuricemia alone. These exploratory findings suggest that metabolic factors may play a role in defining the immunological profile of PsA and warrant prospective validation in larger cohorts. Owing to the cross-sectional design, this study does not allow inference of causal relationships between hyperuricemia and cytokine alterations.<\/jats:p>","DOI":"10.3390\/diseases14060199","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:33:14Z","timestamp":1780479194000},"page":"199","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pro-Inflammatory Synergy Between IL-17, IL-1 and Hyperuricemia in Psoriatic Arthritis: Clinical Implications of a Pilot Study"],"prefix":"10.3390","volume":"14","author":[{"given":"Larisa Ionela","family":"Suiu","sequence":"first","affiliation":[{"name":"Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentin Ananu","family":"Vreju","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1374-276X","authenticated-orcid":false,"given":"Adina","family":"Turcu-Stiolica","sequence":"additional","affiliation":[{"name":"Biostatistics Department, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"},{"name":"Health Economics and Outcomes Research Department, Faculty of Medicine, \u201cIuliu Ha\u0163ieganu\u201d University of Medicine and Pharmacy Cluj-Napoca, Victor Babes Street No. 8, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Elena","family":"Bita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-6138","authenticated-orcid":false,"given":"Mihail Virgil","family":"Boldeanu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina Lucia","family":"Ciurea","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/03009742.2025.2465014","article-title":"Sex distribution in psoriatic arthritis: Systematic literature review","volume":"54","author":"Firlatan","year":"2025","journal-title":"Scand. J. Rheumatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1002\/msc.1692","article-title":"Outcome measures in psoriatic arthritis: Where next?","volume":"20","author":"Hackett","year":"2022","journal-title":"Musculoskelet. Care"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Azuaga, A.B., Ram\u00edrez, J., and Ca\u00f1ete, J.D. (2023). Psoriatic arthritis: Pathogenesis and targeted therapies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054901"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"adv00566","DOI":"10.2340\/00015555-3879","article-title":"Epidemiology, comorbidity and risk factors for psoriatic arthritis","volume":"101","author":"Maximilian","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e002960","DOI":"10.1136\/rmdopen-2022-002960","article-title":"High burden of polypharmacy and comorbidity in psoriatic arthritis","volume":"9","author":"Albrecht","year":"2023","journal-title":"RMD Open"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.31138\/mjr.2506241.dtt","article-title":"Difficult-to-treat psoriatic arthritis: The road so far","volume":"35","author":"Dimopoulou","year":"2024","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_7","first-page":"1611","article-title":"Psoriatic arthritis: One year in review 2022","volume":"40","author":"Cigolini","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Rodr\u00edguez, G., and Puig, L. (2023). Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210305"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1007\/s11547-025-02086-9","article-title":"Evaluation of IL-17 and IL-23 inhibitors on nail and enthesis involvement in early psoriatic arthritis by ultrasonography","volume":"130","author":"Ruscitti","year":"2025","journal-title":"Radiol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: Recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","article-title":"IL-17 in the immunopathogenesis of spondyloarthritis","volume":"14","author":"Taams","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Cole, S., Murray, J., Simpson, C., Okoye, R., Tyson, K., Griffiths, M., Baeten, D., Shaw, S., and Maroof, A. (2020). Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.585134"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"154855","DOI":"10.1016\/j.cyto.2019.154855","article-title":"Functional significance of MAIT cells in psoriatic arthritis","volume":"125","author":"Raychaudhuri","year":"2020","journal-title":"Cytokine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Tissue-resident enthesis \u03b3\u03b4 T cells produce IL-17A independently of IL-23R","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Navarro-Comp\u00e1n, V., Puig, L., Vidal, S., Ram\u00edrez, J., Llamas-Velasco, M., Fern\u00e1ndez-Carballido, C., Almod\u00f3var, R., Pinto, J.A., Gal\u00edndez-Aguirregoikoa, E., and Zarco, P. (2023). The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1191782"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105092","DOI":"10.1016\/j.jbspin.2020.105092","article-title":"The role of interleukin-1 family members in hyperuricemia and gout","volume":"88","author":"Liu","year":"2021","journal-title":"Jt. Bone Spine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41423-025-01358-8","article-title":"IL-1 family cytokines in inflammation and immunity","volume":"22","author":"Garlanda","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/febs.16888","article-title":"Interleukin-1 family cytokines at the crossroads of microbiome regulation","volume":"291","author":"Basavarajappa","year":"2024","journal-title":"FEBS J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/annrheumdis-2021-221801","article-title":"EULAR\/ACR points to consider for IL-1 mediated diseases","volume":"81","author":"Romano","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.amjms.2025.02.006","article-title":"Associations between psoriasis, psoriatic arthritis and hyperuricemia: A systematic review and meta-analysis","volume":"369","author":"Liu","year":"2025","journal-title":"Am. J. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3899\/jrheum.170384","article-title":"Characteristics and outcome of psoriatic arthritis patients with hyperuricemia","volume":"45","author":"AlJohani","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e003428","DOI":"10.1136\/rmdopen-2023-003428","article-title":"Impact of hyperuricemia in psoriatic arthritis treated with secukinumab","volume":"9","author":"Felten","year":"2023","journal-title":"RMD Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/15353702221110666","article-title":"Acute joint swelling in psoriatic arthritis: Flare or \u201cpsout\u201d","volume":"247","author":"Galozzi","year":"2022","journal-title":"Exp. Biol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.clinthera.2023.07.017","article-title":"Utility of musculoskeletal ultrasound in psoriatic arthritis","volume":"45","author":"Hum","year":"2023","journal-title":"Clin. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/1744666X.2016.1215245","article-title":"Psoriatic arthritis: Lessons from imaging studies","volume":"13","author":"Mathew","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1007\/s11547-022-01568-4","article-title":"Nail and enthesis assessment by ultrasonography","volume":"127","author":"Ruscitti","year":"2022","journal-title":"Radiol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e005785","DOI":"10.1136\/rmdopen-2025-005785","article-title":"Ultrasound-defined phenotypes in psoriatic arthritis","volume":"11","author":"Zabotti","year":"2025","journal-title":"RMD Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis (CASPAR)","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000427","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis","volume":"3","author":"Terslev","year":"2017","journal-title":"RMD Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/annrheumdis-2018-213609","article-title":"Ultrasound definition and scoring for enthesitis","volume":"77","author":"Balint","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.47162\/RJME.64.4.11","article-title":"Time to redefine hyperuricemia?","volume":"64","author":"Vreju","year":"2023","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Ahmad, M.I., Masood, S., Furlanetto, D.M., and Nicolaou, S. (2021). Urate crystals beyond joints. Front. Med., 8.","DOI":"10.3389\/fmed.2021.649505"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5114\/ada.2024.139123","article-title":"A retrospective analysis of comorbidities in patients with psoriasis","volume":"41","author":"Huang","year":"2024","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_34","first-page":"84","article-title":"Current characteristics of a population of psoriatic arthritis and gender disparities","volume":"9","author":"Menis","year":"2023","journal-title":"J. Clin. Transl. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/1756-185X.13265","article-title":"Hyperuricemia in Asian patients with psoriatic arthritis","volume":"21","author":"Lai","year":"2018","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.7150\/ijms.88447","article-title":"IL1A regulates inflammation in gout through Toll-like receptor pathways","volume":"21","author":"Liu","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/imm.13858","article-title":"Downregulation of type I interferon signalling by urate in PBMCs","volume":"174","author":"Badii","year":"2024","journal-title":"Immunology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce IL-17 production from \u03b3\u03b4 T cells","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nri3707","article-title":"The IL-23\u2013IL-17 immune axis","volume":"14","author":"Gaffen","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/15257770802138558","article-title":"Uric acid: The oxidant\u2013antioxidant paradox","volume":"27","author":"Sautin","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"14147","DOI":"10.1016\/S0021-9258(18)98655-2","article-title":"IL-1 receptor antagonist inhibits IL-1 binding","volume":"266","author":"Granowitz","year":"1991","journal-title":"J. Biol. Chem."},{"key":"ref_43","first-page":"388","article-title":"Inflammasome activators induce IL-1\u03b1 secretion","volume":"36","author":"Yazdi","year":"2012","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Fusco, R., Siracusa, R., Genovese, T., Cuzzocrea, S., and Di Paola, R. (2020). Role of NLRP3 inflammasome in diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124223"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"38622","DOI":"10.1038\/srep38622","article-title":"Targeting ASC in NLRP3 inflammasome in gout","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Boutet, M.-A., Nerviani, A., Gallo Afflitto, G., and Pitzalis, C. (2018). Role of IL-23\/IL-17 axis in psoriasis and PsA. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020530"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cytogfr.2025.01.002","article-title":"Interleukin-17 in inflammatory diseases","volume":"83","author":"Saran","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"104351","DOI":"10.1016\/j.phrs.2019.104351","article-title":"IL-17A neutralization in gout inflammation","volume":"147","author":"Raucci","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for psoriatic arthritis management","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez, J., Azuaga-Pi\u00f1ango, A.B., Celis, R., and Ca\u00f1ete, J.D. (2021). Cardiovascular risk and obesity in psoriatic arthritis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.742713"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2007.01.011","article-title":"Leptin control of regulatory T cells","volume":"26","author":"Procaccini","year":"2007","journal-title":"Immunity"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Liu, R., and Nikolajczyk, B.S. (2019). Tissue immune cells in obesity inflammation. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01587"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.46497\/ArchRheumatol.2025.10934","article-title":"Immune response and cytokine pathways in psoriatic arthritis","volume":"40","author":"Nas","year":"2025","journal-title":"Arch. Rheumatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/rheumatology\/keaa039","article-title":"Enthesitis in psoriatic arthritis (Part 1): Pathophysiology","volume":"59","author":"Araujo","year":"2020","journal-title":"Rheumatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","article-title":"IL-23\u2013IL-17 pathway in axial spondyloarthritis","volume":"15","author":"Sieper","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10067-022-06061-x","article-title":"Psoriatic arthritis with hyperuricemia","volume":"41","author":"Widawski","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Dasc\u0103lu, R.C., B\u0103rbulescu, A.L., Dinescu, S.C., Bita, C.E., Stoica, L.E., and Vreju, F.A. (2024). Subclinical Enthesopathy in Psoriasis\u2014An Ultrasonographic Study. Med. Sci., 12.","DOI":"10.3390\/medsci12030040"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"Tissue-resident T cells in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of BMI on biologic efficacy in psoriasis","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Egeberg, A., Merola, J.F., Sch\u00e4kel, K., Puig, L., Mahar, P.D., Wang, I.Y., Pavo, I., Schuster, C., and Griffiths, C.E.M. (2023). Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1092688"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Campos, C., Fito-Manteca, M.C., Valero-Mart\u00ednez, C., Garc\u00eda-Carazo, S., Almod\u00f3var, R., D\u00edaz-Cerezo, S., Moyano, S., Cobo, A., Aguirregabiria, I., and P\u00e9rez-Rambla, C. (2026). Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study). Front. Med., 12.","DOI":"10.3389\/fmed.2025.1704081"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"G\u00e1lvez, I., Navarro, M.C., Mart\u00edn-Cordero, L., Otero, E., Hinchado, M.D., and Ortega, E. (2022). Obesity and weight loss in inflammatory regulation. Nutrients, 14.","DOI":"10.3390\/nu14030612"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e13975","DOI":"10.1111\/obr.13975","article-title":"Weight loss-associated remodeling of adipose immunometabolism","volume":"26","author":"Basso","year":"2025","journal-title":"Obes. Rev."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/6\/199\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:11:23Z","timestamp":1780481483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/6\/199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":66,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["diseases14060199"],"URL":"https:\/\/doi.org\/10.3390\/diseases14060199","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}